Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;25(10):456–460. doi: 10.1002/clc.4960251004

C‐reactive protein as a marker for active coronary artery disease in patients with chest pain in the emergency room

Rasmi Magadle 1,, Paltiel Weiner 1, Marinella Beckerman 1, Noa Berar‐Yanay 1
PMCID: PMC6654685  PMID: 12375803

Abstract

Background: Markers of inflammation, such as C‐reactive protein (CRP), were found to be related to risk for cardiovascular disease (CVD) events in patients with angina pectoris. In addition, recent studies have shown that, in the case of atherosclerosis, increased CRP concentration reflects the inflammatory condition of the vascular wall.

Hypothesis: The study was undertaken to determine whether CRP levels in individuals with chest pain attending the emergency room (ER) may be used as a marker of active CVD.

Methods: Serum CRP level was measured in 226 of 326 consecutive patients (128 men, 98 women; mean age 61.3 ± 5.9 years; range 19–87 years) referred to the ER with chest pain. The decision whether to admit or release the subjects was determined without taking the CRP level into account. Follow‐up was then performed for 1 year.

Results: Eighty‐four patients were admitted to the hospital. Of these, 9 with acute coronary syndrome (ACS) had very high levels of CRP (25–40 mg/l), 35 had had an acute coronary event within the preceding 3 months, with levels of CRP 14–20 mg/l. Only eight patients with nonsignificant CVD had elevated CRP levels. Twenty‐eight subjects who were released from the ER had elevated CRP levels (7–14 mg/l); 8 of these, in addition to 4 subjects with normal CRP levels, had a late coronary event.

Conclusion: This study indicates that in patients referred to the ER with chest pain and no other indication for hospitalization, a normal level of CRP suggests safe release. Most hospitalized patients with normal CRP will not have acute coronary syndrome. Patients who will develop early coronary events have very high CRP levels. High serum CRP level, after excluding other inflammatory sources, was proven to be a sensitive diagnostic and prognostic marker for significant coronary disease.

Keywords: chest pain, cardiovascular disease, C‐reactive protein, inflammation, atherosclerosis, emergency room

Full Text

The Full Text of this article is available as a PDF (47.3 KB).

References

  • 1. Braunwald E: Heart Disease: A Textbook of Cardiovascular Medicine, 5th edition, p. 1332 Philadelphia: WB Saunders, 1997. [Google Scholar]
  • 2. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 326: 242–250 [DOI] [PubMed] [Google Scholar]
  • 3. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801–809 [DOI] [PubMed] [Google Scholar]
  • 4. Hendrix MGR, Daemen M, Bruggeman CA: Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol 1991; 138: 563–567 [PMC free article] [PubMed] [Google Scholar]
  • 5. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Marnninen V, Manttari M, Frick MH, Huttunen JK: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273–278 [DOI] [PubMed] [Google Scholar]
  • 6. Patel P, Mendall MA, Carrington D, Strachan DP, Leathan E, Molineaux N, Levy J, Blakeston C, Symour CA, Camm AJ: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995; 311: 711–714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Pepys MB: Acute Phase Proteins in the Acute Response. London: Springer‐Verlag, 1989. [Google Scholar]
  • 8. Pepys MB: The acute phase response and C‐reactive protein In Oxford Textbook of Medicine (Eds. Weatherall DJ, Ledingham JGG, Warrell DA.). New York, N. Y.: Oxford University Press, 1996. [Google Scholar]
  • 9. De Beer FC, Hind DRK, Fox KM, Allan RM, Maseri A, Pepys MB: Measurement of serum C‐reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 238–243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Moti T, Sasaki J, Kawagushi H, Handa K, Takada Y, Matsunaga A, Kono S, Arakawa K: Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995; 129: 234–238 [DOI] [PubMed] [Google Scholar]
  • 11. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC: C‐reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. Br Med J 1996; 312: 1061–1065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Heinrich J, Schulte H, Schönfeld R, Köler E, Assman G: Association of variables of coagulation, fibrinolysis and acute‐phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemostas 1995; 73: 374–378 [PubMed] [Google Scholar]
  • 13. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C‐reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417–424 [DOI] [PubMed] [Google Scholar]
  • 14. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C‐reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–466 [DOI] [PubMed] [Google Scholar]
  • 15. Oltrona L, Ardissimo D, Merlini PA, Spinola A, Chiodo F, Pezzano A: C‐reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol 1997; 80: 1002–1006 [DOI] [PubMed] [Google Scholar]
  • 16. Toss H, Lindhal B, Siegbahn A, Wallentin L: Prognostic influence of increased fibrinogen on C‐reactive protein levels in unstable coronary artery disease: FRISC Study group: Fragmin during instability in coronary artery disease. Circulation 1997; 96: 4204–4210 [DOI] [PubMed] [Google Scholar]
  • 17. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L: Markers of myocardial damage and inflammation in relation to long‐term mortality in unstable coronary artery disease: FRISC Study group: Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343: 1139–1147 [DOI] [PubMed] [Google Scholar]
  • 18. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the MRFIT group : Relation of C‐reactive protein and coronary heart disease in the MRFIT nested case‐control study. Am J Epidemiol 1996; 144: 537–547 [DOI] [PubMed] [Google Scholar]
  • 19. Earl SF, Wayne HG: Serum C‐reactive protein and self‐reported stroke: Findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000; 20: 1052–1056 [DOI] [PubMed] [Google Scholar]
  • 20. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercelloti GM: C‐reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513–520 [PubMed] [Google Scholar]
  • 21. Jacobijn G, Marianne CLS, Marijke F, Gerard JB, Rudi GJW: C‐reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 2000; 20: 1047–1051 [DOI] [PubMed] [Google Scholar]
  • 22. Centers for Disease Control and Prevention : Plan and operation of the Third National Health and Nutrition Examination Survey. 1988–1994. Bethesda, Md.: National Center for Health Statistics, 1994. Vital Health Statistics 1(32). Series 1, No. 32 [Google Scholar]
  • 23. Abbot Laboratories Instruction Manual : Protein C‐reactive TDx/ TDxFLx. Abbot Laboratories, North Chicago, Ill. [Google Scholar]
  • 24. Shine B, De Beer FC, Pepys MB: Solid phase radioimmunoassay for CRP. Clin Chim Acta 1981; 117: 13–23 [DOI] [PubMed] [Google Scholar]
  • 25. Berk BC, Weintraub WS, Alexander W: Elevation of C‐reactive protein in active coronary artery disease. Am J Cardiol 1990; 65: 168–172 [DOI] [PubMed] [Google Scholar]
  • 26. Kushner I, Broder ML, Karp D: Control of the acute phase response: Serum C‐reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978; 61: 235–242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone‐Gastin I, Angioi M, Lozniewsli A, Loubinoux J, Le Faou A, Gueant JL: C‐reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999; 137: 346–351 [DOI] [PubMed] [Google Scholar]
  • 28. Biasucci LM, Vitelli A, Liuzzo G, Altamura A, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A: Elevated levels of interleukin‐6 in unstable angina. Circulation 1996; 94: 874–877 [DOI] [PubMed] [Google Scholar]
  • 29. Dinarello C: Biologic basis for interleukin‐6 in disease. Blood 1996; 87: 2095–2147 [PubMed] [Google Scholar]
  • 30. Pepys MB, Baltz ML: Acute phase proteins with special reference to C‐reactive protein and related proteins (pentaxin) and serum amyloid A protein. Adv Immunol 1983; 334: 141–212 [DOI] [PubMed] [Google Scholar]
  • 31. Lagrand WK, Visser CA, Hermens WT, Niessen HN, Verheugt FW, Wolbink GJ, Hack CE: C‐reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999; 100: 96–102 [DOI] [PubMed] [Google Scholar]
  • 32. Lüscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y: Interaction between endothelium‐derived relaxing and contracting factors in health and cardiovascular disease. Circulation 1993; 87 (suppl): V36–V44 [Google Scholar]
  • 33. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Limores E, Pauget JM, Sabharwal SC, Chesler E, Demots H: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403 [DOI] [PubMed] [Google Scholar]
  • 34. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES